Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Operating costs and expenses:        
Research and development $ (2,205,213) $ (555,740) $ (2,634,494) $ (1,590,823)
IPR&D expense (39,500,000) 0 (39,500,000) 0
General and administrative (1,557,677) (803,399) (2,980,043) (1,738,625)
Loss from operations (43,262,890) (1,359,139) (45,114,537) (3,329,448)
Other income (expense):        
Change in fair value of derviative liability 1,769,275 0 1,905,289 0
Loss on issuance of hybrid debt instrument 0 0 (1,584,218) 0
Loss on conversion of debt (6,187,337) 0 (6,187,337) 0
Other income (expense) 12,863 234,453 (13,551) (225,515)
Interest income 13 914 27 1,088
Interest expense (103,086) (1,386) (348,470) (2,512)
Total other income (expense) (4,508,272) 233,981 (6,228,260) (226,939)
Net loss (47,771,162) (1,125,158) (51,342,797) (3,556,387)
Other comprehensive loss from foreign currency translation adjustment 0 (338,875) 0 (327,054)
Total comprehensive loss $ (47,771,162) $ (1,464,033) $ (51,342,797) $ (3,883,441)
Net loss per share of common stock, basic and diluted $ (6.12) $ (.27) $ (8.28) $ (.84)
Weighted-average shares of common stock outstanding, basic and diluted 7,804,187 4,221,328 6,197,776 4,221,328